NMN/NR and Tadalafil Interaction: Safety, Mechanisms, and Clinical Guidance
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursor dietary supplements sold under various brand names (NR is marketed as Niagen). Tadalafil (brand name Cialis) is an FDA-approved phosphodiesterase type 5 (PDE5) inhibitor prescribed for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension at higher doses. NMN and NR are not FDA-approved drugs; they are regulated as dietary supplements under the Dietary Supplement Health and Education Act, which means they are not subject to the same premarket interaction review as tadalafil (FDA, dietary supplements).
No published human pharmacokinetic study has reported that NMN or NR inhibits or induces CYP3A4, the primary enzyme responsible for tadalafil metabolism. NMN and NR are processed through a nucleoside salvage pathway (conversion to NAD+ via enzymes such as NRK1/NRK2 and NMNAT) that does not overlap with cytochrome P450 metabolism. The clinically relevant question is not a metabolic drug-drug interaction but a pharmacodynamic one: both tadalafil and NAD+ precursors have been associated with modest blood pressure lowering through separate mechanisms, so their effects could theoretically add together in a patient who is also on antihypertensive therapy. This is a plausible, mechanism-based concern rather than an effect that has been directly measured in a trial of the combination, and it should be verified against current product labeling and a pharmacist before assuming it applies to any individual regimen.
Why this question comes up
Tadalafil is a widely prescribed PDE5 inhibitor, and NAD+ precursor supplements have become popular in longevity and metabolic health circles. The demographic overlap is real: men over 40 using tadalafil for erectile dysfunction or BPH are also a common audience for NMN/NR marketing. Because NMN and NR are supplements, the tadalafil prescribing information does not mention them, and no regulatory body has issued specific interaction guidance for this pairing. That gap is why the reasoning below relies on pharmacology and general trial findings rather than a labeled interaction warning.
Do NMN/NR and tadalafil compete for the same metabolic pathway?
Tadalafil is metabolized mainly by CYP3A4. Drugs that strongly inhibit CYP3A4 (certain antifungals, some HIV protease inhibitors) can raise tadalafil blood levels substantially, and the FDA label for tadalafil addresses dose adjustments in that setting. This is an established, labeled interaction and applies to specific prescription drugs, not to NMN or NR.
NMN and NR are absorbed and converted to NAD+ through nucleoside transporters and salvage-pathway enzymes, a route that does not involve cytochrome P450 metabolism as far as published data show. Some small human pharmacokinetic studies of oral NMN and NR exist, but the exact trial identifiers and quantitative findings in earlier drafts of this topic could not be verified against a confirmed source and are not repeated here with specific numbers. The general conclusion that these supplements are not known CYP3A4 substrates or inhibitors is consistent with how they are described in the nutrition and supplement literature, but a pharmacist should still be consulted if a patient is on multiple interacting medications, since absence of evidence is not the same as proof of no effect.
The real concern: additive blood pressure lowering
Tadalafil causes vasodilation by inhibiting PDE5, which increases cyclic GMP in vascular smooth muscle. This is why tadalafil carries an absolute contraindication with organic nitrates (nitroglycerin, isosorbide products), a labeled interaction that is well established and should never be overridden by self-directed supplement use.
NAD+ precursors are proposed to support endothelial function through sirtuin activation and nitric oxide synthase pathways, and some small trials of NR have measured blood pressure or vascular stiffness as secondary endpoints. Reported changes in these trials have generally been small and in some cases not statistically significant, and rodent studies have shown larger blood-pressure effects at doses well above typical human supplement intake. Because the specific trial numbers cited in earlier versions of this topic could not be confirmed against a verifiable source, they are described here only in general terms: modest, mechanistically plausible blood-pressure lowering from NAD+ precursors has been reported in some studies, but it is not established as a reliable, dose-consistent clinical effect in humans at standard supplement doses.
Combining two agents that can each modestly lower blood pressure raises a theoretical additive risk. For a normotensive person not on other blood-pressure medication, an extra reduction of a few mmHg from each agent is unlikely to be clinically meaningful. For a person already on antihypertensive therapy, especially if resting blood pressure is on the lower end of normal, the combination deserves closer attention because the margin before symptomatic hypotension is smaller.
Evidence-status assessment: NMN/NR plus tadalafil
| Claim | Status | Basis | What to verify |
|---|---|---|---|
| NMN/NR does not inhibit CYP3A4 or alter tadalafil blood levels | Plausible, not formally established in a dedicated interaction trial | General pharmacology of the nucleoside salvage pathway; no CYP3A4 mechanism identified in supplement literature | Confirm current tadalafil label language and check for any updated interaction warnings before assuming no effect |
| Tadalafil can cause a small blood pressure reduction on its own | Established (labeled effect) | FDA-approved prescribing information for tadalafil | Check the current label for the specific magnitude and population studied |
| NAD+ precursors can produce a small blood pressure or vascular effect in some studies | Observational/early trial evidence, mixed significance | Small human trials and animal studies referenced in NAD+ supplement literature | Confirm which specific trial, dose, and population before quoting a number |
| Tadalafil plus nitrates causes dangerous hypotension | Established (FDA contraindication) | FDA tadalafil labeling | Not applicable to NMN/NR directly, but relevant if a patient is on both nitrates and NAD+ supplements |
| Combining tadalafil with NMN/NR causes clinically significant additive hypotension in most patients | Not established | No dedicated combination trial identified | This is a pharmacodynamic hypothesis, not a demonstrated clinical outcome; individualized risk should be assessed by a prescriber |
| NMN and NR behave identically for interaction purposes | Plausible based on shared metabolic pathway | Both converge on the NAD+ salvage pathway | Reasonable working assumption, but head-to-head interaction data for either compound with tadalafil do not exist |
Who should be more cautious
People taking organic nitrates together with tadalafil should not add NAD+ precursors, or any other supplement, without prescriber input, because the nitrate-tadalafil combination is already a labeled contraindication regardless of any additional agent. People on antihypertensive medication, alpha-blockers (such as tamsulosin or doxazosin), or with a history of orthostatic symptoms should discuss starting NMN or NR with their prescriber and consider home blood pressure monitoring during the first weeks. People with no other blood-pressure-lowering medications and normal baseline blood pressure appear to be at lower theoretical risk, but "lower risk" is not the same as "no risk," and monitoring is still a reasonable precaution given the lack of dedicated interaction data.
A practical monitoring approach
There is no FDA-cleared or guideline-endorsed dosing algorithm for combining NMN/NR with tadalafil, because NMN and NR are unregulated supplements. A cautious, common-sense approach used in some longevity-medicine practice settings involves starting any new NAD+ precursor at a lower dose, checking seated blood pressure at home for the first one to two weeks, and watching for dizziness, lightheadedness on standing, or unusually low readings. This is site judgment and general clinical caution, not a validated protocol, and it should be discussed with the prescriber managing the tadalafil prescription, particularly if the patient is also on other blood-pressure medications.
When to stop and seek care
Stop the supplement and contact a clinician, or seek urgent care, if any of the following occur while taking tadalafil and an NAD+ precursor together: fainting or near-fainting, systolic blood pressure persistently below 90 mmHg, chest pain, new visual disturbance, or a severe headache that worsens on standing. Patients taking tadalafil 20 mg for pulmonary arterial hypertension have less cardiovascular reserve and should be especially attentive to these symptoms, and any supplement use in that population should be reviewed with the prescribing specialist before starting.
What is established, what is plausible, and what is not known
Established: tadalafil is metabolized by CYP3A4 and has labeled contraindications with nitrates; NMN and NR are regulated as supplements without FDA premarket interaction review. Plausible but not proven in humans taking both agents together: additive blood pressure lowering from combining a PDE5 inhibitor with an NAD+ precursor. Not established: any specific magnitude of combined blood pressure drop, any case report of harm from this specific combination, or a validated dose-timing strategy that eliminates the theoretical risk. Readers should not treat the mechanistic reasoning in this article as equivalent to clinical trial evidence of the combination itself.
Frequently asked questions
Can I take NMN or NR with tadalafil?
Does NMN affect the CYP3A4 enzyme that metabolizes tadalafil?
Is this combination dangerous if I take blood pressure medication?
Should I tell my doctor I take NMN or NR before starting tadalafil?
Are NMN and NR the same for interaction purposes?
References
- U.S. Food and Drug Administration. Dietary supplement regulation overview. https://www.fda.gov/food/dietary-supplements
- U.S. Food and Drug Administration. Drug approvals and databases (for current tadalafil labeling). https://www.fda.gov/drugs/drug-approvals-and-databases
- ClinicalTrials.gov. Search for registered NAD+ precursor trials. https://clinicaltrials.gov/search?term=NAD%2B%20precursor
Note for editorial and medical review: several specific figures, trial identifiers, and attributed quotations present in the prior draft (including named-physician quotations and precise percentage/mmHg values) could not be verified against confirmed primary sources and have been removed or replaced with general, appropriately hedged language. Before publication, please confirm current tadalafil label interaction language and identify verifiable primary sources for any NMN/NR blood pressure trial data that should be cited with specific numbers.